Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs CODX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: AYTU 5 – 1 CODX Matrix Metrics: AYTU 7 – 3 CODX

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Co-Diagnostics, Inc. (CODX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas CODX carries 51.6/100 (HOLD) at $0.23 (15.4x Forward P/E, -3415.8% operating margin).

  • Composite vs. Pillar Nuance: While CODX currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -3415.8% operating margin) and revenue trajectory (+6.4% vs. +94.6% YoY).
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CODX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs CODX
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
CODX NASDAQ
Co-Diagnostics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.23
-11.68% 1D
Market Cap $2.3M
TTM Revenue $858,888
Forward P/E 15.4x
Beta / 30D Vol 2.93β · 148% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 55.0 Fund 54.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.1%), weak momentum, RSI 22
RSI-14: 21.8 · SMA20: $0.39 · SMA50: $0.78

6-Pillar Scorecard Institutional Category Breakdown (AYTU 5 – 1 CODX)

Columns: Metric · AYTU · CODX
1. Valuation Multiples AYTU
Forward P/E 9.2x 15.4x
Trailing P/E 9.2x 15.4x
PEG Ratio N/M N/M
EV / Revenue 0.3x N/M
2. Growth & Scale CODX
Revenue Growth (YoY) +6.4% +94.6%
Earnings Growth (YoY) +0.0% +30.8%
TTM Revenue (USD) $58M $858,888
Market Cap $19.6M $2.3M
3. Profitability & Quality AYTU
Gross Margin 64.0% 20.3%
Operating Margin -14.4% -3415.8%
Net Profit Margin -24.8% 0.0%
Return on Equity (ROE) -52.5% -192.8%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$28M EBITDA
Cash Flow Margin -2.4% N/A
Net Cash / Leverage $4.9M Net Cash $6.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AYTU
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 270.2% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (7) vs CODX (3)
Institutional Metric AYTU CODX Criterion Row Edge
Market Capitalization
Scale
$19.6M $2.3M Larger Scale AYTU
Trailing P/E Ratio
Valuation
9.2x 15.4x Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x 15.4x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% +94.6% Higher Growth CODX
Operating Margin (TTM)
Profitability
-14.4% -3415.8% Higher Margin AYTU
Net Profit Margin
Profitability
-24.8% 0.0% Higher Margin CODX
Return on Equity (ROE)
Capital Efficiency
-52.5% -192.8% Higher ROE AYTU
52-Week Range Position
Momentum
5% ($2–$3) 0% ($0–$14) Stronger Trend AYTU
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 2.93β · 148% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 51.6 / 100 (HOLD) Higher Composite CODX
Trailing 12M Revenue (USD)
Operating Scale
$58M $858,888 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 20.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$28M EBITDA ($6.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AYTU +53.81 pp
AYTU: -11.27% · CODX: -65.08%
3M Horizon AYTU +58.56 pp
AYTU: -23.31% · CODX: -81.87%
6M Horizon AYTU +69.52 pp
AYTU: -13.81% · CODX: -83.33%
1Y Horizon AYTU +26.46 pp
AYTU: -12.14% · CODX: -38.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue CODX Revenue AYTU Op. Margin CODX Op. Margin Margin Leader
FY2019 $10M $0M -230.1% -2741.6% AYTU
FY2020 $30M $70M -76.5% 55.9% CODX
FY2021 $70M $100M -89.7% 47.1% CODX
FY2022 $100M $30M -113.7% -78.8% CODX
FY2023 $110M $10M -15.9% -626.9% AYTU
FY2024 $70M $0M -2.4% -1023.7% AYTU
FY2025 $70M $0M -11.8% -8058.8% AYTU
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CODX BREAKDOWN
173d in phase · OBV DISTRIBUTION
Current IV 270.2%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CODX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
CODX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.3M market capitalization and -3415.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs CODX Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Co-Diagnostics, Inc. (CODX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas CODX carries 51.6/100 (HOLD) at $0.23 (15.4x Forward P/E, -3415.8% operating margin). Composite vs. Pillar Nuance: While CODX currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -3415.8% operating margin) and revenue trajectory (+6.4% vs. +94.6% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CODX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CODX leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with CODX at +94.6% YoY revenue growth and +30.8% YoY earnings growth on $858,888 TTM revenue (20.3% gross margin, -3415.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while CODX shifted -85.7%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CODX.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas CODX trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus CODX (-192.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, CODX carries 270.2% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.93β · 148% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.